

Hypertension in adults (update) Committee meeting

Date: 10/10/2018

Location: NGC Boardroom, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:	
Anthony Wierzbicki (Chair)	(Present for notes 1–5)
Liz Clark	(Present for notes 1–4D)
Elizabeth Denver	(Present for notes 1–5)
Mark Glover	(Present for notes 1–5)
Judith Magowan	(Present for notes 4A–4D)
Terry McCormack	(Present for notes 1–5)
Irene McGill	(Present for notes 1–5)
Richard McManus	(Present for notes 1–5)
Lucy Pollock	(Present for notes 1–5)
Mark Shapley	(Present for notes 1–5)
Alison Warren	(Present for notes 1–5)

In attendance:		
Catherine Baden-Daintree	Senior Medical Editor, NICE	(Present for notes 1–5)
Caroline Kier	Guideline Commissioning Manager, NICE	(Present for notes 1–5)
Edgar Masanga	Business Analyst, NICE	(Present for notes 1–5)
Rebecca Boffa	Senior Research Fellow, NGC	(Present for notes 1–5)
Serena Carville	Guideline Lead, NGC	(Present for notes 1–5)
Margaret Constanti	Senior Health Economist, NGC	(Present for notes 1–5)
Meredith Faust	Project Manager, NGC	(Present for notes 1–5)
Christopher Floyd	Clinical Trainee, NGC	(Present for notes 1–5)
Rafina Yarde	Research Fellow, NGC	(Present for notes 1–5)

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the eleventh meeting on Hypertension in adults. The committee members and attendees introduced themselves.

The Chair informed the committee that no apologies had been received.

The Chair informed the committee that Bryan Williams has resigned as a member of the Hypertension in adults guideline committee.

The Chair outlined the objectives of the meeting, which included the final health economic modelling results for initiating treatment for hypertension; malignant hypertension; and reviewing research recommendations, the full list of recommendations and the committee discussion documents for diagnosis, targets and relaxation therapies.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initiation of hypertensive treatment, malignant hypertension, diagnosis, targets and relaxation therapies.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Role with NICE	Type of interest	Description of interest	Relevant dates		Comments
				Interest arose	Interest ceased	
Terry McCormack	Committee member	Direct non-financial	Carr S, Shaikh R, O'Donnell R, McCormack T. The Awareness and Implementation of the AAGBI/BHS Guideline on Management of Hypertension Before Elective Surgery in the Hull York Medical School Region. <i>Journal of Human Hypertension</i>	2018		Specific. No action other than the process of open declaration

			(2018) 32:S9 P-04. doi.org/10.1038/s41371-018-0109-3			
		Direct non-financial	Shaikh R, Carr S, O'Donnell R, McCormack T. The Significance of Blood Pressure in Cancellations of Elective Surgery: An Audit of the Hull York Medical School Region Following Recent New Guidelines. <i>Journal of Human Hypertension</i> (2018) 32:S9 P-03. doi.org/10.1038/s41371-018-0109-3	2018		Specific. No action other than the process of open declaration
		Indirect financial	The Whitby Group Practice Research Fund has received a payment from Roche for work on a guideline to manage high blood pressure caused by treatments for cervical and ovarian cancer.	06/04/18	Ongoing	Specific. No action other than the process of open declaration
		Indirect financial	The Whitby Group Practice Research Fund has received additional payments from Sanofi and Weight Watchers for research activities.	23/08/18	05/09/18	Non-specific. No action other than the process of open declaration
		Direct financial	I have received speaker fees and expenses from AstraZeneca for a talk on hyperkalaemia management.	26/09/18	26/09/18	Non-specific. No action other than the process of open declaration

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Questions and discussion

- A. Margaret Constanti, Senior Health Economist at the NGC, presented the health economic modelling results for the review question, 'At what blood pressure or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated?' The committee discussed and asked questions about the health economic model results and drafted recommendations.
- B. Rafina Yarde, Research Fellow at the NGC, presented the updated clinical evidence for the review question 'What factors indicate the need for same-day specialist review (including the possible presence of malignant or accelerated hypertension)?' The committee discussed and asked questions about the evidence and drafted recommendations.
- C. The committee discussed the drafted research recommendations.
- D. The committee discussed the recommendations and rationale for 3.3 review question, 'What is the optimum blood pressure target for adults with treated primary hypertension?'
- E. It was noted that reruns of all of the review question searches have been completed but yielded no relevant studies to include either clinically or economically.

5. Any other business

None.

Date of next meeting: 16/11/2018

Location of next meeting: NGC Boardroom, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE